In July, the China Food and Drug Administration (CFDA) approved the registration of four gene sequencing products, opening the gene sequencing market, frozen over the previous six months, and reversing its previous conservative and cautious attitude, Shanghai-based China Business News reports.
In 2013, China’s non-invasive prenatal testing market had a scale of about 1 billion yuan (US$161.9 million), with BGI and Berry Genomics taking a dominant market share. Non-invasive prenatal testing is increasingly being adopted by high-risk pregnant women for the screening of common fetal chromosomal aneuploidies. Read more.
Prenatal Information Research Consortium 